Full-Time

Senior Therapeutic Specialist

HIV Treatment

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$133.2k - $172.4k/yr

+ Discretionary annual bonus + Stock-based long-term incentives

Company Historically Provides H1B Sponsorship

West Palm Beach, FL, USA

In Person

On-site within the assigned West Palm Beach territory; travel within the area required.

Bachelor's, Master's

Category
Sales & Account Management (1)
Required Skills
FDA Regulations

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • 6+ Years with BS/BA OR 4+ Years with MS/MA
  • Ability to engage in travel as may be reasonably required, including regular travel within the assigned area (and, to the extent applicable, satisfaction of any requirements associated with such travel)
  • Satisfaction of any onsite visitation requirements of healthcare practitioners within an assigned area, if applicable (which may include vaccinations, drug and background screenings, and any other requirements that certain healthcare practitioners may adopt)
  • To perform this job successfully, the employee must be able to perform each essential duty satisfactorily.
  • Reasonable accommodation may be made to enable individuals with disabilities to perform essential functions.
  • A valid driver's license is required
Responsibilities
  • Build strong relationships and engage healthcare providers across various touchpoints, ensuring a holistic understanding of their needs and maximizing the impact of Gilead's products
  • Develop and execute a comprehensive territory business plan that meets customer needs and achieves sales goals. Continuously monitor sales progress, adjusting strategies as necessary to meet and exceed targets
  • Maintain a deep understanding of Gilead's products, competitive products, and the complexities associated with the therapeutic area’s disease state
  • Actively promote the appropriate use of Gilead products to healthcare professionals, adhering to Corporate, PhRMA, and OIG guidelines
  • Partner effectively with local cross-functional colleagues (field reimbursement managers, medical scientists and other field team members) to ensure a seamless customer experience through access, acquisition, administration and operational support with Gilead products
  • Collaborate externally with healthcare organizations and partner companies, including co-promotion efforts, to enhance product reach and drive sales results
  • Demonstrate the ability to build and maintain strong internal and external working relationships, ensuring seamless collaboration across departments and organizations
  • Model and uphold Gilead's compliance standards and ethical behavior, demonstrating peer leadership within the team
  • Ensure adherence to regulatory agency, state, federal, and company policies, procedures, and business ethics. This includes timely reporting of adverse events to Gilead's Drug Safety and Public Health department
  • Ensures all department personnel are fully informed of and in compliance with Gilead commercial compliance policy, all applicable federal and state laws and guidance relating to product promotion and information dissemination, including, but not limited to, the Federal Food, Drug, and Cosmetic Act, the Food and Drug Administration's implementing regulations, the Federal Anti-Kickback Statute, the False Claims Act, PhRMA, Corporate Code of Business Conduct and the Office of the Inspector General's Compliance Program Guidance for Pharmaceutical Manufacturers
  • Leverage advanced influencing and relationship skills to drive sales outcomes
  • Build solid relationships and establish long-term partnerships with healthcare providers.
  • Perform all required administrative tasks, including reporting call activity and customer information in the designated systems, submitting expenses, and managing the territory budget.
  • Exhibit a passion for learning and retaining technical and scientific product information, staying updated on industry trends and changes in the therapeutic area
  • Demonstrate a self-motivated drive to surpass personal goals and consistently exceed performance standards while working autonomously
  • Experience in selling a Buy and Bill product with proven sales success
  • Actively contribute to Gilead's ongoing Inclusion & Diversity efforts, fostering an inclusive environment within the team and the broader organization
Desired Qualifications
  • BA or BS degree
  • A minimum of 5 years of pharmaceutical, biotech or healthcare industry sales experience
  • Possess superior selling skills focused on highly competitive markets
  • Proven and consistent track record of meeting/exceeding sales objectives, preferably in specialty markets
  • Successful performance and collaborative leadership with account-focused cross-functional local teams
  • Experience in selling injectable physician-administered products
  • Familiarity with the managed care landscape and its impact on business
  • Create Inclusion - knowing the business value of diverse teams, modeling inclusion, and embedding the value of diversity in the way they manage their teams.
  • Develop Talent - understand the skills, experience, aspirations, and potential of their employees and coach them on current performance and future potential.
  • Empower Teams - connect the team to the organization by aligning goals, purpose, and organizational objectives and holding them to account.
  • Actively contribute to Gilead's ongoing Inclusion & Diversity efforts, fostering an inclusive environment within the team and the broader organization.
  • Exhibit a passion for inclusion & diversity efforts, fostering an inclusive environment within the team and the broader organization.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $7.8 billion, beating estimates on August 4.
  • PrEP sales exceeded $1 billion, and Yeztugo reached $232 million in Q2.
  • FDA accepted weekly Yeztugo tablets, with a February 2, 2027 PDUFA date.

What critics are saying

  • Merck’s Idvynso and GSK’s Cabenuva attack Gilead’s HIV moat this year.
  • Biktarvy exclusivity ends in 2036, concentrating replacement pressure on next-generation regimens.
  • HIV supplies about 70% of revenue, so a franchise stumble hits valuation hard.

What makes Gilead Sciences unique

  • Biktarvy anchors Gilead’s HIV franchise, generating $3.8 billion in Q2 2026.
  • Yeztugo made Gilead the first six-month injectable PrEP leader in 2026.
  • Lenacapavir enables weekly oral and biannual dosing, differentiating Gilead’s HIV platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 8th, 2026
Gilead raises 2026 outlook on HIV and PrEP strength, targets $30B in sales

Gilead Sciences reported second-quarter 2026 results that exceeded expectations, with revenues of $7.8 billion, up 10% year over year, and a non-GAAP loss per share of $6.75 beating consensus estimates. The company raised its full-year guidance for product sales excluding Veklury to $29.8 billion to $30.1 billion, an increase of $350 million at the midpoint. HIV sales drove growth, rising 12% in the quarter. Quarterly PrEP sales surpassed $1 billion for the first time, putting the prevention business at a $4 billion annual run rate. Gilead now expects full-year HIV sales to increase 9% to 10%, up from its prior 8% outlook. Biktarvy generated $3.8 billion in sales, whilst newer product Yeztugo delivered $232 million. The company maintained its approximately $1 billion full-year Yeztugo sales target, with more than 70% of users returning for reinjection at six months.

Yahoo Finance
Aug 4th, 2026
Gilead Q2 sales rise 8% to $7.8B, beating estimates despite acquisition-related loss

Gilead Sciences reported second-quarter product sales rose 8%, driven by double-digit growth in HIV drugs. Overall revenue increased 10% to $7.8 billion, surpassing Wall Street's $7.4 billion estimate. HIV sales grew 12%, whilst cancer drug Trodelvy and liver disease drug Livdelzi also performed strongly. HIV prevention drug Yeztugo generated $232 million, exceeding forecasts, whilst Descovy sales jumped 48% to $967 million. The company posted a quarterly loss due to acquisition costs. Gilead narrowed its projected full-year loss and slightly raised its revenue outlook to between $30.1 billion and $30.4 billion. The California-based biotech firm expressed confidence in achieving $1 billion in annual Yeztugo sales.

Yahoo Finance
Aug 3rd, 2026
California Supreme Court rules for Gilead, rejects 'duty to innovate' in case with 24,000 HIV patients

California's Supreme Court ruled 6-1 that drugmakers have no legal duty to develop safer alternatives to existing safe medications, siding with Gilead Sciences in a closely watched case. The decision dismissed negligence claims from approximately 24,000 patients using Gilead's HIV drug. Patients argued the company should have developed an alternative with fewer side effects more than 20 years ago. Justice Joshua Groban wrote that imposing a "duty to innovate" would require juries to second-guess complex scientific judgements. He warned it could create substantial burdens and risk adverse consequences for pharmaceutical innovation and public health. The ruling reversed a February 2024 appeals court decision. Dozens of trade groups and major drugmakers, including Pfizer, Merck and Johnson & Johnson, supported Gilead's appeal. HIV drugs accounted for 70% of Gilead's $29.4 billion revenue last year.

MarketBeat
Jul 28th, 2026
Gilead Sciences (GILD) expected to post quarterly earnings on Monday.

Gilead Sciences (GILD) expected to post quarterly earnings on Monday. July 28, 2026 Key points. * Gilead Sciences is expected to report Q2 2026 results after Monday's market close. Analysts forecast revenue of approximately $7.40 billion and a loss of $7.25 per share; the earnings call is scheduled for Tuesday, August 4. * Gilead's latest quarter exceeded expectations, with EPS of $2.03 versus the $1.91 consensus and revenue of $6.96 billion, up 4.4% year over year. * The stock recently traded at $133.57, while analysts maintain a "Moderate Buy" consensus and an average price target of $158.30. Gilead also pays a quarterly dividend of $0.82 per share, yielding about 2.5%. * MarketBeat previews top five stocks to own in August. Gilead Sciences (NASDAQ:GILD - Get Free Report) is expected to be announcing its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect Gilead Sciences to announce earnings of ($7.2479) per share and revenue of $7.4001 billion for the quarter. Gilead Sciences has set its FY 2026 guidance at -1.050-0.650 EPS. Investors can check the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET. Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts' consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the previous year, the business earned $1.81 EPS. The company's quarterly revenue was up 4.4% compared to the same quarter last year. On average, analysts expect Gilead Sciences to post $-1 EPS for the current fiscal year and $10 EPS for the next fiscal year. Gilead Sciences price performance. GILD stock traded up $3.05 during trading hours on Tuesday, hitting $133.57. 2,655,524 shares of the stock traded hands, compared to its average volume of 7,097,293. The stock has a 50-day simple moving average of $129.56 and a 200 day simple moving average of $135.68. The company has a market cap of $165.84 billion, a P/E ratio of 18.19 and a beta of 0.32. Gilead Sciences has a one year low of $108.46 and a one year high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences announces dividend. The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were given a dividend of $0.82 per share. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences's dividend payout ratio (DPR) is 44.69%. Insider activity. In other news, CEO Daniel Patrick O'day sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the transaction, the chief executive officer owned 607,133 shares in the company, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider directly owned 124,234 shares in the company, valued at $15,395,077.28. The trade was a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,000 shares of company stock worth $8,687,140 over the last quarter. Corporate insiders own 0.30% of the company's stock. Hedge funds weigh in on Gilead Sciences. Several institutional investors and hedge funds have recently bought and sold shares of the business. Vermillion & White Wealth Management Group LLC lifted its position in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $26,000. Swiss RE Ltd. purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $31,000. Mcguire Capital Advisors Inc. purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $43,000. Finally, Palisade Asset Management LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at approximately $46,000. Hedge funds and other institutional investors own 83.67% of the company's stock. Analysts set new price targets. Several equities analysts have recently issued reports on the stock. Maxim Group raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Citigroup lifted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a "buy" rating in a research report on Monday, April 13th. Leerink Partners cut Gilead Sciences from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. The Goldman Sachs Group boosted their target price on Gilead Sciences from $125.00 to $130.00 and gave the stock a "neutral" rating in a research report on Friday, April 17th. Finally, Royal Bank Of Canada reduced their target price on Gilead Sciences from $122.00 to $120.00 and set a "sector perform" rating for the company in a report on Tuesday, July 7th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $158.30. About Gilead Sciences. Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world. Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Gilead Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list. While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Business Insider
Jul 25th, 2026
Gilead Sciences (GILD) gets a Hold from RBC Capital.

Gilead Sciences (GILD) gets a Hold from RBC Capital. Jul. 25, 2026, 08:45 AM RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences on July 23 and set a price target of $120.00. The company's shares closed yesterday at $130.86. * Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions * Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks According to TipRanks, Abrahams is a 5-star analyst with an average return of 14.5% and a 54.40% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine. In addition to RBC Capital, Gilead Sciences also received a Hold from Goldman Sachs's Salveen Richter in a report issued on July 20. However, on July 23, BMO Capital assigned a Buy rating to Gilead Sciences (NASDAQ: GILD). Based on Gilead Sciences' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.96 billion and a net profit of $2.02 billion. In comparison, last year the company earned a revenue of $6.67 billion and had a net profit of $1.32 billion Read More on GILD: